CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

Adjuvant tamoxifen therapy substantially decreases the risk of recurrence and mortality in women with hormone (estrogen and/or progesterone) receptor-positive breast cancer. Previous studies have suggested that metabolic conversion of tamoxifen to endoxifen by cytochrome P450 2D6 (CYP2D6) is require...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2012-03, Vol.104 (6), p.452-460
Hauptverfasser:	RAE, James M, DRURY, Suzy, HAYES, Daniel F, STEARNS, Vered, THIBERT, Jacklyn N, HAYNES, Ben P, SALTER, Janine, SESTAK, Ivana, CUZICK, Jack, DOWSETT, Mitch
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anastrozole Antineoplastic agents Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - epidemiology Breast Neoplasms - genetics Breast Neoplasms - prevention & control Chemotherapy Chemotherapy, Adjuvant Clinical trials Cytochrome P-450 CYP2D6 - genetics Drug therapy Female Genotype Genotype & phenotype Germ-Line Mutation Glucuronosyltransferase - genetics Humans Medical sciences Middle Aged Mortality Neoplasm Recurrence, Local - enzymology Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - prevention & control Neoplasm Staging Nitriles - therapeutic use Odds Ratio Pharmacology. Drug treatments Postmenopause Randomized Controlled Trials as Topic Receptors, Estrogen - analysis Receptors, Progesterone - analysis Risk Assessment Risk Factors Tamoxifen - therapeutic use Triazoles - therapeutic use Tumors United Kingdom Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!